Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics-Reference-Cited by-同舟云学术

Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics

Published:2022-01-11 Issue:4 Volume:25 Page:713-719
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Sutera Philip,Van Der Eecken Kim,Kishan Amar U.^ORCID,Hamid Anis,Grist Emily,Attard Gerhardt^ORCID,Lotan Tamara,Mendes Adrianna A.,Paller Channing J.^ORCID,Carducci Michael A.,Ross Ashley^ORCID,Wang Hao^ORCID,Pienta Ken^ORCID,Feng Felix Y.^ORCID,Antonarakis Emmanuel S.,Ost Piet^ORCID,Song Daniel Y.,Greco Stephen,Deville Curtiland^ORCID,DeWeese Theodore,Tran Phuoc T.,Deek Matthew P.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-021-00484-4.pdf

Reference26 articles.

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.

2. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36:1080–7.

3. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51.

4. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353–66.

5. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650–9.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis;British Journal of Cancer;2024-09-02

2. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer;European Urology Oncology;2024-04

3. The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease;Journal of Nuclear Medicine;2024-02-15

4. Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer;Cancers;2023-12-21

5. Trends in the treatment of metastatic castration-sensitive prostate cancer;Onkologie;2023-11-29